Holen Sie sich die Stockscreener-App
429.82
1.13%
4.82
Handel nachbörslich:
429.76
-0.06
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$425.00
Offen:
$422.37
24-Stunden-Volumen:
953.13K
Relative Volume:
0.70
Marktkapitalisierung:
$109.09B
Einnahmen:
$12.34B
Nettoeinkommen (Verlust:
$4.34B
KGV:
25.48
EPS:
16.8685
Netto-Cashflow:
$3.71B
1W Leistung:
+1.39%
1M Leistung:
-3.18%
6M Leistung:
+4.97%
1J Leistung:
+0.05%
1-Tages-Spanne:
$421.11
$431.94
1-Wochen-Bereich:
$412.27
$433.94
52-Wochen-Spanne:
$362.50
$507.92
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-03-10 | Bestätigt | Oppenheimer | Outperform |
| 2026-02-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Biotech Stocks To Watch NowMay 9th - MarketBeat
Vertex Pharma stock (US92532F1003): Q1 2026 earnings beat lifts shares on growth in new disease area - AD HOC NEWS
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharma stock (US92532F1003): Mixed Q1 results and 2026 guidance reiterated - AD HOC NEWS
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Secures Reimbursement Agreement fo - GuruFocus
April 2026 — CDMO Opportunities And Threats Report - Bioprocess Online
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Vertex Pharmaceuticals Stock Analysis: 1991 IPO Growth and 2026 OutlookNews and Statistics - IndexBox
Vertex (VRTX) Q1 2026 Earnings Call Transcript - AOL.com
Vertex Pharmaceuticals (NASDAQ: VRTX) affiliate proposes stock sales; insider sales listed - Stock Titan
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy (VRTX) - Seeking Alpha
Michel Lagarde At Vertex Pharmaceuticals Acquires Stock Options Worth $9K - Benzinga
BRUCE SACHS Backs Up Beliefs With A Notable Acquisition Of Vertex Pharmaceuticals Stock Options Worth $9K - Benzinga
Vertex Pharmaceuticals Posts Mixed Q1; Investors Focus On Non-CF Pipeline For Growth - Sahm
German reimbursement deal for Vertex’ Casgevy - The Pharma Letter
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Vertex Pharmaceuticals (VRTX) and Sotera Health (SHC) - The Globe and Mail
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany - BioSpace
Vertex secures German reimbursement deal for gene therapy By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and Merck & Company (MRK) - The Globe and Mail
Is It Too Late To Consider Vertex Pharmaceuticals (VRTX) After Recent Share Price Weakness - Yahoo Finance
Vertex Pharmaceuticals: Investment Returns and Future Outlook - Intellectia AI
Is This Millionaire-Maker Biotech Stock a Buy Right Now? - The Motley Fool
Is This Millionaire-Maker Biotech Stock a Buy Right Now? - The Motley Fool
Vertex Pharmaceuticals Incorporated 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VRTX) 2026-05-06 - Seeking Alpha
Insider Sell: Sangeeta Bhatia Sells Shares of Vertex Pharmaceuti - GuruFocus
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q) - marketscreener.com
Vertex (VRTX) director receives options, defers vested shares into stock units - Stock Titan
Vertex (NASDAQ: VRTX) director receives new equity grants - Stock Titan
Vertex director Sangeeta Bhatia sells $134,746 of company stock By Investing.com - Investing.com South Africa
Vertex Pharmaceuticals Insider Sold Shares Worth $469,222, According to a Recent SEC Filing - marketscreener.com
Director Schneider shifts 796 Vertex (VRTX) shares into deferred units - Stock Titan
Vertex Pharmaceuticals EVP Joy Liu sells $469,222 in shares By Investing.com - Investing.com Nigeria
Vertex Pharmaceuticals EVP Joy Liu sells $469,222 in shares - Investing.com
Director at Vertex (NASDAQ: VRTX) receives 2,866 fully vested options - Stock Titan
Vertex (VRTX) director reports stock grant and 796-share deferral - Stock Titan
Vertex EVP Joy Liu (NASDAQ: VRTX) sells 1,104 shares in planned trade - Stock Titan
Vertex director Sangeeta Bhatia sells $134,746 of company stock - Investing.com
Vertex (VRTX) director gets 2,866 fully vested stock options grant - Stock Titan
Vertex (VRTX) director Alan Garber granted RSUs and fully vested options - Stock Titan
Lloyd Carney of Vertex (VRTX) receives fully vested options grant - Stock Titan
Vertex (VRTX) director granted 943 RSUs and sells 318 shares - Stock Titan
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex (NASDAQ: VRTX) Q1 profit climbs to $1.03B on $3.0B sales - Stock Titan
Vertex Pharmaceuticals Confident in Emerging Renal Franchise, Oppenheimer Says - Moomoo
VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth - sharewise.com
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings - Benzinga
Narrow-Moat Vertex's Strong Cash Flows From CF Franchise Support Portfolio Diversification - Morningstar
Vertex Dips On Mixed First-Quarter Report; But There's A Silver Lining - Investor's Business Daily
Vertex earnings get muted investor response - BioPharma Dive
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vertex Pharmaceuticals Inc-Aktie (VRTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Liu Joy | EVP and Chief Legal Officer |
May 01 '26 |
Sale |
425.02 |
1,104 |
469,222 |
20,729 |
| Bhatia Sangeeta N. | Director |
May 04 '26 |
Sale |
423.73 |
318 |
134,746 |
4,924 |
0.82%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):